Skip to main content

Table 2 Correlation of NAP1L1 expression with clinicopathological characteristics of patients with Breast cancer

From: NAP1L1 interacts with hepatoma-derived growth factor to recruit c-Jun inducing breast cancer growth

Characteristics n NAP1L1 expression
High Low p
Age(year)
 < 50 43 15 (34.9%) 28 (65.1%) 0.067
 ≥ 50 54 10 (18.5%) 44 (81.5%)
Clinical stage
 I 8 1 (12.5%) 7 (87.5%) 0.025
 II 53 9 (17.0%) 44 (83.0%)
 III 36 15 (41.7%) 21 (58.3%)
Tumor scale
 ≤ 3 cm 53 13 (24.5%) 40 (75.5%) 0.758
 > 3 cm 44 12 (27.3%) 32 (72.7%)
Histological grade
 I 29 9 (31.0%) 20 (69.0%) 0.439
 II–III 68 16 (23.5%) 52 (76.5%)
Vital states
 Die 26 13 (50.0%) 13 (50.0%) 0.001
 Alive 71 12 (16.9%) 59 (83.1%)
ER
 Negative 36 12 (33.3%) 24 (66.7%) 0.191
 Positive 61 13 (21.3%) 48 (78.7%)
PR
 Negative 40 14 (35.0%) 26 (65.0%) 0.082
 Positive 57 11 (19.3%) 46 (80.7%)
HER2
 Negative 60 15 (25.0%) 45 (75.0%) 0.825
 Positive 37 10 (27.0%) 27 (73.0%)
Lymph metastasis
 No 32 6 (18.8%) 26 (81.2%) 0.267
 Yes 65 19 (29.2%) 46 (70.8%)